Trevi Therapeutics

93 articles with Trevi Therapeutics

• Trevi Therapeutics Announces First Quarter 2022 Financial Results and Business Update

  5/12/2022

  Trevi Therapeutics, Inc. announced financial results for the quarter ended March 31, 2022, as well as provided business updates.

• Trevi Therapeutics to Report Q1 2022 Financial Results and Provide a Corporate Update on May 12, 2022

  5/5/2022

  Trevi Therapeutics, Inc. announced that management will host a conference call and live audio webcast on Thursday, May 12, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the first quarter ended March 31, 2022.

• Trevi Therapeutics to Present at Upcoming May Meetings

  5/3/2022

  Trevi Therapeutics, Inc. today announced that senior management will present at the following May meetings.

• Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market

  4/7/2022

  Trevi Therapeutics, Inc. announced that it has entered into a definitive agreement with certain healthcare-focused institutional investors for the purchase, in a private placement priced at-the-market under Nasdaq rules, of 4,580,526 shares of common stock at a purchase price of $1.90 per share, and pre-funded warrants to purchase up to an aggregate of 24,379,673 shares of common stock at a purchase price of $1.899 per warrant, for gross proceeds of approximately $55 million.

• Trevi Therapeutics to Participate at 21st Annual Needham Virtual Healthcare Conference

  4/5/2022

  Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing an investigational oral therapy Haduvio™ for pruritus in prurigo nodularis and chronic cough in idiopathic pulmonary fibrosis.

• Trevi Therapeutics Hosting Key Opinion Leader Webinar on the Seriousness of Chronic Cough in Idiopathic Pulmonary Fibrosis (IPF)

  3/22/2022

  Webinar will be held on Wednesday, March 30, 2022 , from 8:00 a.m. to 9:00 a.m. EDT.

• Trevi Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Business Update

  3/17/2022

  Today, Trevi announced financial results for the quarter and year ended December 31, 2021, as well as provided business updates.

• Trevi Therapeutics Concludes Enrollment for Phase 2 CANAL Trial in IPF Chronic Cough

  3/15/2022

  Today, Trevi announced that it concluded enrollment early for its Phase 2 Cough And NALbuphine (CANAL) trial for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) patients following the previously announced statistically significant efficacy results from the interim analysis (N=26).

• Trevi Therapeutics to Report Q4 and Year End 2021 Financial Results and Provide a Corporate Update on March 17, 2022

  3/9/2022

  Trevi announced that management will host a conference call and live audio webcast on Thursday, March 17, 2022, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the fourth quarter and full year ended December 31, 2021. 

• Trevi Therapeutics Reports Statistically Significant Result on Interim Analysis from the Ph2 CANAL Trial of Nalbuphine ER in the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis

  2/24/2022

  Trevi Therapeutics, Inc. today announced positive interim analysis results of the Phase 2 Cough And NALbuphine (CANAL) trial of its investigational therapy Haduvio™ (nalbuphine ER) in idiopathic pulmonary fibrosis patients (IPF).

• Trevi Therapeutics Completes Enrollment for Phase 2b/3 PRISM Study in Chronic Pruritus in PN

  2/1/2022

  Today, Trevi announced that it has completed enrollment in its Phase 2b/3 PRISM trial for pruritus associated with prurigo nodularis (PN) and expects to report top-line data in the second quarter of 2022.

• Trevi Therapeutics Announces Clinical Trial Updates for Lead Indications

  1/5/2022

  Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions.

• Trevi Therapeutics to Attend Multiple Conferences in January 2022

  12/16/2021

   Trevi Therapeutics, Inc. (Nasdaq: TRVI) is a clinical-stage biopharmaceutical company developing an investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions.

• Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

  11/15/2021

  Trevi Therapeutics, Inc. today announced that Dr. Bill Forbes , Chief Development Officer, will be presenting at the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases taking place from November 16-18, 2021 in Boston, MA.

• Trevi Therapeutics Announces Third Quarter 2021 Financial Results and Business Update

  11/10/2021

  Trevi Therapeutics, Inc. today announced financial results for the quarter ended September 30, 2021, as well as provided business updates.

• Trevi Therapeutics to Present at Stifel 2021 Virtual Healthcare Conference

  11/9/2021

  Trevi Therapeutics, Inc. today announced that senior leadership members will participate in a virtual fireside chat, as well as host investor meetings, at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021.

• Trevi Therapeutics to Report Q3 2021 Financial Results and Provide a Corporate Update on Wednesday, November 10, 2021

  11/3/2021

  Trevi Therapeutics, Inc. today announced that management will host a conference call and live audio webcast on Wednesday, November 10 at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the third quarter ended September 30, 2021.

• Trevi Therapeutics to Present at 11th World Congress on Itch (WCI)

  10/13/2021

  Trevi Therapeutics, Inc. today announced that Dr. Bill Forbes , Chief Development Officer, will present as part of a virtual viewpoint session at the 11th World Congress on Itch (WCI) taking place from October 22-23, 2021.

• Trevi Therapeutics Participating in Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference

  10/7/2021

   Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that senior management will be available for virtual one-on-one meetings at Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference.

• Trevi Therapeutics Announces $11.8 Million Private Placement Priced At-the-Market

  10/1/2021

  Trevi Therapeutics, Inc. announced that it has entered into a definitive agreement with a healthcare-focused institutional investor, for the purchase, in a private placement priced at-the-market under Nasdaq rules, of 2,373,201 shares of common stock and accompanying warrants to purchase an aggregate of 4,746,402 shares of common stock.